Generex In Biomarker Partnership
Generex Biotechnology, a Canada-based company with operations in Worcester, is joining with Amarantus Biosciences Inc. of California in developing a biomarker test to determine which diabetic patients could respond well to an insulin spray product.
Generex Oral-lyn, currently in Phase III clinical trials, is intended to provide a simple delivery system for insulin. The biomarker test would make use of a therapeutic protein that Amarantus is developing.
Generex has already licensed its drug delivery technology to Amarantus for use in delivering other drugs and agreed to spend $5 million for joint research efforts on the technology.
Along with the new agreement, Amerantus announced that it has executed an agreement with the University of Massachusetts Medical School in Worcester to license intellectual property developed by the school to advance its diagnostic program.
WBJ Web Partners
Most Recent
Most Recent
0 Comments